Jennison Associates LLC Cuts Position in Encompass Health Corporation $EHC

Jennison Associates LLC lowered its position in Encompass Health Corporation (NYSE:EHC) by 37.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 560,779 shares of the company’s stock after selling 333,732 shares during the quarter. Jennison Associates LLC’s holdings in Encompass Health were worth $59,521,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in EHC. Millennium Management LLC increased its position in shares of Encompass Health by 140.0% in the third quarter. Millennium Management LLC now owns 1,223,665 shares of the company’s stock valued at $155,430,000 after buying an additional 713,738 shares in the last quarter. 8 Knots Management LLC purchased a new position in shares of Encompass Health in the second quarter valued at $78,644,000. Alliancebernstein L.P. increased its position in shares of Encompass Health by 23.4% in the third quarter. Alliancebernstein L.P. now owns 2,515,878 shares of the company’s stock valued at $319,567,000 after buying an additional 476,564 shares in the last quarter. Thrivent Financial for Lutherans increased its position in shares of Encompass Health by 57.8% in the third quarter. Thrivent Financial for Lutherans now owns 1,194,859 shares of the company’s stock valued at $151,544,000 after buying an additional 437,464 shares in the last quarter. Finally, Raymond James Financial Inc. increased its position in shares of Encompass Health by 34.8% in the third quarter. Raymond James Financial Inc. now owns 1,541,336 shares of the company’s stock valued at $195,780,000 after buying an additional 397,694 shares in the last quarter. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Encompass Health Trading Down 2.4%

Encompass Health stock opened at $100.15 on Friday. The stock has a market cap of $9.96 billion, a PE ratio of 18.08, a P/E/G ratio of 1.97 and a beta of 0.75. The stock has a 50-day moving average price of $103.05 and a 200 day moving average price of $107.65. Encompass Health Corporation has a 52 week low of $92.77 and a 52 week high of $127.99. The company has a current ratio of 1.08, a quick ratio of 1.08 and a debt-to-equity ratio of 0.76.

Encompass Health (NYSE:EHC) last posted its quarterly earnings data on Thursday, April 30th. The company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.51 by $0.09. The firm had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Encompass Health had a return on equity of 18.20% and a net margin of 9.54%.The firm’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.37 EPS. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. Equities research analysts predict that Encompass Health Corporation will post 5.91 earnings per share for the current fiscal year.

Encompass Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Wednesday, April 1st were given a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date was Wednesday, April 1st. Encompass Health’s dividend payout ratio (DPR) is currently 13.72%.

Analyst Ratings Changes

A number of research analysts have recently weighed in on EHC shares. Wall Street Zen cut Encompass Health from a “buy” rating to a “hold” rating in a research report on Saturday, April 11th. Barclays raised their price target on Encompass Health from $150.00 to $153.00 and gave the company an “overweight” rating in a research report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Encompass Health presently has an average rating of “Buy” and an average price target of $146.33.

Insider Transactions at Encompass Health

In related news, Treasurer Edmund Fay sold 11,937 shares of Encompass Health stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $107.00, for a total transaction of $1,277,259.00. Following the completion of the sale, the treasurer owned 89,325 shares in the company, valued at approximately $9,557,775. This trade represents a 11.79% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Mark J. Tarr sold 150,000 shares of Encompass Health stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $111.64, for a total value of $16,746,000.00. Following the sale, the chief executive officer owned 377,070 shares of the company’s stock, valued at approximately $42,096,094.80. This represents a 28.46% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 1.80% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.